Dosage in Research Models

Research Dose Ranges by Route

The following dose parameters are drawn from the published preclinical and pilot research literature. They represent what was administered to animals in experimental settings. They do not constitute recommendations for human use, and BPC-157 is not approved for human therapeutic use by any regulatory authority.

Intraperitoneal (IP) — most common preclinical route

The dose most frequently cited across the rodent literature is 10 µg/kg/day.^{[1][4][6][14]} A lower-dose bracket of 10 ng/kg/day was tested in the same-study comparisons and consistently produced results similar to the 10 µg/kg arm.^{[1][4][6][14]} An extreme low-dose test — 10 pg/kg — was administered in the Achilles tendon-to-bone healing study and still demonstrated measurable functional improvement.^[1]

Oral / drinking water

BPC-157 was administered via drinking water in multiple GI and musculoskeletal studies, typically at the same 10 µg/kg and 10 ng/kg dose brackets.^[6][7][14] Its unusual gastric stability — attributed to four proline residues in its structure — made oral delivery experimentally viable where most short peptides would be rapidly degraded.^[8][17]

Intramuscular (IM)

The gastric ulcer protection studies used IM delivery at 400–800 ng/kg, a notably lower effective dose bracket than the IP range used in musculoskeletal models.^[5] This suggests route-dependent pharmacokinetics that influence the effective dose — a distinction the research has not fully characterized.

Intragastric

Used in the same gastric ulcer models at 400–800 ng/kg.^[5] Intraperitoneal delivery was noted to require higher doses for equivalent GI mucosal protection than direct intragastric delivery, consistent with first-pass considerations.

Intravenous (IV)

Used in the 2022 pharmacokinetic characterization study in rats and dogs.^[13] The highest dose tested in a human pilot was 20 mg IV, administered as a single infusion.^[15]

Spinal cord injury acute model

A single intraperitoneal dose of 200 µg/kg or 2 µg/kg administered 10 minutes after compression injury in rats produced sustained functional recovery through 360 days.^[10] This is notably higher than the chronic daily dosing used in most musculoskeletal models.

In vitro (fibroblast culture)

BPC-157 was applied to rat Achilles tendon fibroblasts at 0.1, 0.25, and 0.5 µg/mL concentrations. The 7-fold increase in GHR mRNA and protein was observed at 0.5 µg/mL by day 3.^[2] In vitro concentrations are not directly translatable to in vivo dose requirements.

Pharmacokinetics: Half-Life, Bioavailability, and Distribution

The pharmacokinetic profile of BPC-157 was characterized in a 2022 Frontiers in Pharmacology study using rats and beagle dogs across IV and IM administration routes.^[13]

Elimination half-life

Following IV administration, the elimination half-life (t½) was under 30 minutes in both rats and dogs.^[13] This is a short half-life relative to most therapeutic peptides, indicating rapid systemic clearance.

Intramuscular bioavailability

IM bioavailability was 14.49–19.35% in rats and 45.27–50.56% in beagle dogs.^[13] The approximately 3-fold difference between species is notable and raises questions about bioavailability in humans that remain uncharacterized in the published literature.

Distribution

Following IV dosing, the highest concentrations were found in the kidney and liver within 3 minutes of administration, consistent with a rapidly distributed compound that clears primarily via renal and hepatic pathways.^[13]

Metabolism and excretion

BPC-157 is metabolized rapidly to its constituent amino acids.^[13] Elimination occurred primarily via urine and bile. No active metabolites have been described in the published literature.

Pharmacokinetic linearity

Pharmacokinetics were linear across the dose range studied, meaning the compound did not show evidence of dose-dependent saturation of absorption, distribution, or elimination pathways within the tested range.^[13]

Stability context

The peptide's four proline residues confer resistance to proteolytic cleavage that would otherwise rapidly degrade most 15-amino acid peptides in gastric or intestinal environments.^[8][17] This gastric stability is mechanistically distinct from systemic pharmacokinetics — the peptide is stable in GI fluids but still cleared rapidly from systemic circulation once absorbed.

No human pharmacokinetic data exist. The ADME profile of BPC-157 in humans is uncharacterized. The 2025 Inflammopharmacology commentary on BPC-157 GI cytoprotection listed 'no human biodistribution data' as a primary critical gap.^[17] Any extrapolation from rat or dog PK to human PK would be speculative.

Routes Studied and Administration Context

The breadth of routes tested in BPC-157 research is unusual for an unapproved compound. The following routes appear in the published literature:

• Intraperitoneal — the dominant route in rodent research, accounting for the majority of published findings^{[1][4][6][10][14]}
• Oral gavage / drinking water — used successfully in GI and musculoskeletal models owing to gastric stability^{[5][6][7][14]}
• Intramuscular — characterized pharmacokinetically in rats and dogs; used therapeutically in gastric ulcer models^[5][13]
• Intravenous — used in pharmacokinetic studies and in the highest-dose human IV pilot (20 mg)^[13][15]
• Local / topical at wound site — applied directly in fistula healing models^[7]
• Intragastric — used alongside IM in gastric ulcer protection studies^[5]
• Rectal enema — the route used in the Phase II PL 14736 ulcerative colitis trial^[8]
• Intra-articular — one human pilot explored knee injection in 12 patients^[15]
• Intravesicular — one human pilot explored bladder instillation^[15]

The effective dose in the gastric ulcer IM model (400–800 ng/kg) is several orders of magnitude lower than the IP dose used in most musculoskeletal models (10 µg/kg), suggesting that route, tissue target, and model type all materially affect the dose-response relationship.^[5][1]

Human pilot summary. The three published human pilots administered BPC-157 via intra-articular injection, intravesicular instillation, and intravenous infusion (up to 20 mg), respectively.^[15] No major adverse events were reported in any pilot. Sample sizes were very small (n=2 to n=16 across pilots). These pilots are exploratory safety observations, not efficacy data sufficient for clinical conclusions.

Regulatory and Purity Context

The FDA's Category 2 designation (September 2023) reflects a determination that BPC-157 lacks sufficient human safety data to permit compounding in licensed US pharmacies under Sections 503A and 503B.^[15] This means that any BPC-157 obtained outside a licensed pharmaceutical manufacturing process — including from research chemical suppliers — has no regulatory quality assurance framework behind it.

Manufacturing purity and peptide sequence verification are identified concerns in the regulatory record.^[15] Unverified sources may supply truncated peptide sequences, racemized amino acids, or impure batches. The correct BPC-157 sequence is GEPPPGKPADDAGLV. Verification of this sequence requires analytical methods such as HPLC and mass spectrometry — methods that are not routinely applied to commercially available research-grade peptide products.

WADA's S0 prohibition renders BPC-157 a banned substance for competitive athletes at all times, with no Therapeutic Use Exemption pathway available.^[15] USADA has specifically stated that no safe dose has been established in humans.

Long-term safety in any species is poorly characterized. The preclinical literature does not contain systematic toxicology studies examining repeat-dose administration over extended periods in a rigorous regulatory-toxicology format. The absence of reported toxicity in short-to-medium-duration animal studies cannot be directly interpreted as safety in chronic human use contexts.